ClinicalTrials.Veeva

Menu
G

GCP Clinical Research | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Etrasimod
Guselkumab
Golimumab
Elagolix
Methotrexate
HZN-825
Fezolinetant
MTX
ABX464
Bexotegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 44 total trials

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in...

Enrolling
Coeliac Disease
Celiac Disease
Dietary Supplement: SIGE
Drug: Placebo

The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux diseas...

Begins enrollment in 1 month
GERD (Gastroesophageal Reflux Disease)
Drug: Linaprazan glurate 50 mg Twice Daily (BID)
Drug: Lansoprazole 30 mg Once Daily (QD)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Active, not recruiting
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Active, not recruiting
Colitis, Ulcerative
Drug: Placebo
Drug: JNJ-77242113

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Active, not recruiting
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Active, not recruiting
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Placebo
Drug: Camoteskimab

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: Lutikizumab Matching Placebo
Drug: Adalimumab Matching Placebo

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficac...

Enrolling
Colitis Ulcerative
Drug: Placebo
Drug: Dupilumab

This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in...

Enrolling
Ulcerative Colitis
Drug: PF-07054894
Drug: Placebo

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Active, not recruiting
Gout
Drug: Methotrexate
Biological: Pegloticase

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease...

Active, not recruiting
Celiac Disease
Drug: TAK-101
Dietary Supplement: Gluten

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.The objective is to evaluate...

Enrolling
Moderately to Severely Active Crohn Disease
Drug: Obefazimod
Other: Placebo

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment o...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: PLN-74809
Drug: Placebo

Trial sponsors

AbbVie logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
A
Astellas logo
A
Sanofi logo
Takeda logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems